CRISPR/Cas9-engineered Salmonella phage displaying the human antimicrobial peptide LL-37 on its surface combined phage-mediated bacterial lysis with AMP membrane disruption for enhanced pathogen killing.
Phage + AMP = superweaponCRISPR engineering put the human antimicrobial peptide LL-37 on a virus that already kills bacteria — attacking from both inside and outside
What the researchers found
CRISPR/Cas9-engineered Salmonella phage displaying LL-37: combined phage lysis + AMP membrane disruption for enhanced dual-mechanism bacterial killing.
Why it matters
Neither phages nor AMPs alone are perfect antibiotics. Combining them creates a biological weapon that attacks bacteria from both inside and outside simultaneously.
How the study worked
CRISPR/Cas9 engineering of Salmonella phage for LL-37 surface display, characterization of phage-AMP construct, and antimicrobial activity comparison vs phage alone and LL-37 alone.
What this study cannot tell us
Salmonella-specific phage. Engineering for other pathogens needs separate development. Phage-AMP stability and in vivo efficacy need assessment.
How to read the evidence
Proof-of-concept combining two antimicrobial platforms through CRISPR engineering.
When this study was published
Published in 2025.
The bigger picture
CRISPR-engineered phage-AMP hybrids represent the next evolution in biological antibiotics — precision genetic engineering creating enhanced anti-pathogen weapons.
Questions still open
- Could this approach be applied to phages targeting other ESKAPE pathogens?
- Would LL-37-displaying phages work in animal infection models?
- Can multiple AMPs be displayed simultaneously for broader spectrum?
Common questions
What is a phage-AMP hybrid?
Is this genetic engineering safe?
Read the original research
CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity.
International journal of antimicrobial agents, 67(4), 107734
Citation
Jo, Su Jin; Park, Se Chang; Kim, Sang Guen. (2026). CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity.. International journal of antimicrobial agents, 67(4), 107734. https://doi.org/10.1016/j.ijantimicag.2026.107734